Yuri Matusov is a Respiratory physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 63 publications with 1,484 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8700 Beverly Blvd Ste Ac1150
West Hollywood, CA 900481804
Telephone
310-423-8784Provider last certified this registry record 30 Jul 2025.
Clinical trials
- Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension
Sponsor: Yuri Matusov
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Actelion Pharmaceuticals US, Inc.Program year20254 payments
- United Therapeutics CorporationProgram year20256 payments
- Inquis Medical, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
52.3%Prostacycline Vasodilator22.3%Tyvaso Dpi100%Part D≥20 patientsFactor Xa inhibitor19.8%Eliquis66%Xarelto35%Part D<11 patients+ 1 more class in this area
Cardiovascular
17.1%Endothelin Receptor Antagonist12.6%Ambrisentan67%Opsumit33%Part D<11 patientsLoop diuretic4.5%Furosemide100%Part D<11 patientsRespiratory
11.7%Corticosteroid6.1%Trelegy Ellipta100%Part D<11 patientsbeta2-Adrenergic Agonist3.2%Albuterol Sulfate Hfa100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 26-A-22803-ACC BASELINE CHARACTERISTICS BY AGE IN FDA CLINICAL TRIAL PULMONARY ARTERIAL HYPERTENSION DATA
Journal of the American College of Cardiology
2026 - Risk Factors for Adverse Outcomes in Connective Tissue Disease-Associated Pulmonary Hypertension
Reviews in Cardiovascular Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Paul Noble, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”